June 15th, 2009 -- Posted in Prostate |
Department of Family and Community Medicine, Eastern Virginia Medical School, 825 Fairfax Avenue, Norfolk, VA 23507, USA. This Email greet is being protected from spam bots, you desideratum Javascript enabled to Direction it Cancer-Specific mortality is projected to be only 1% in 15 years in approximately 75% of Patients with screen-detected localized Prostate Cancer (LPC). Nearly 94% of Patients select care even though Therapy damages Health-Related superiority of life. No observations are obtainable apropos what Survival further Patients expected from Treatment.
Objectives: A self-administered mailed examine was sent to 184 men with newly diagnosed LPC to ask Patients about expected Survival with curing versus observation.
continue reading »
Tags:
cancer,
expected,
patients,
survival
Related posts
May 11th, 2009 -- Posted in Prostate |
NEW YORK (Reuters Health) - Prostate-Specific (PSA) Spread predicts worse overall Survival in men with Metastatic Prostate Cancer, according to a Report in in the April 20th Journal of Clinical Oncology. “We demonstrated that the PSA course acutance proposed by the Prostate Cancer Working Group (PCWG-2008), which I coauthored, seems to be very strongly associated with Survival,” Dr. Maha Hussain from University of Michigan, Ann Arbor, Michigan, told Reuters Health. Dr. Hussain and colleagues correlated the rare definitions of extending as predictors of overall Survival by using observations from two awaited Southwest Group intergroup, appearance III Trials.
In the initially try (S9346), PSA development was decidedly significantly associated with succeeding endanger of Death, with the highest danger ratios occurring when the PCWG-2008 clarification of PSA progression was used (that is, an heighten of PSA by at least 25% and at least 2 ng/mL). Similarly, in the surrogate proof (S9916) PSA progression was significantly associated with resulting risk of Death, and the associations were nearly the same for the PCWG-2008 Definition and with the Definition using an increase of PSA by at least 25% and at least 5 ng/mL. Results from the latter Trial, the investigators say, suggest that care standard does not upset the association between PSA rise and Survival.
continue reading »
Tags:
associated,
hussain,
least,
progression,
Prostate,
reuters,
survival
Related posts
May 7th, 2009 -- Posted in Prostate |
Dendreon Corporation recently reported encouraging slant III Office Results for Provenge, a vaccine that uses a Patient’s own vaccinated arrangement to match Advanced . The Results put forward craving to men with Advanced Disease, though it may be some take before they see the vaccine, which has yet to be submitted to the FDA for approval. Over 500 men with Advanced Prostate Cancer that was no longer responding to Hormone cure were enrolled in the Study. Two thirds of the men received 3 infusions of Provenge over the speed of a month; the other third received a placebo.
The men who received Provenge infusions lived an common of 4 months longer than men who were getting the placebo. The 3-year Survival tariff for the men getting Provenge was 32%, compared to 23% for placebo. “These Results corroborate the Clinical value of Provenge to keep up Survival in Patients with Advanced Prostate Cancer. Moreover, it validates the longstanding but indefinable desire to harness a Patient’s own invulnerable modus operandi to confront Cancer,” said one of the go first researchers, Philip Kantoff, MD, peak of the Prostate Cancer Program and manager of the strife of durable Tumor Oncology at the Dana-Farber Cancer Institute and Harvard Medical School.
continue reading »
Tags:
advanced,
cancer,
Prostate,
provenge,
results,
survival
Related posts
April 29th, 2009 -- Posted in Prostate |
April 28 (Bloomberg) — ’s Prostate Cancer psychotherapy Provenge, the Essential malignancy-fighting immunotherapy, extended men’s lives by four months in a Study. Shares mow as much as 65 percent as investors waited for the data, then more than doubled in after-hours trading. Dendreon plunged $9.74, or 45 percent, to $11.81 before was halted at 1:27 p.m. New York time, and kill as much as $14.05. The Nasdaq Stock Market investigated 2 minutes advantage of transactions in Dendreon and let them be upstanding after initially suspecting they were the effect of a brokerage Error, the reciprocity said in a statement. Shares rose to $27.20 at 6:25 p.m. in extended trading, an extend of 130 percent.
Men with Advanced Tumors had a median Survival of 25.8 months with Provenge, compared with 21.7 months with a placebo in a 512-Patient try the body presented at the meeting. Provenge, if approved, would be the maiden hypnotic designed to trail the body’s unsusceptible scheme to seizure Cancer Cells delight in a virus.
continue reading »
Tags:
cancer,
dendreon,
interview,
provenge,
shares,
survival,
taxotere
Related posts
April 20th, 2009 -- Posted in Prostacet |
According to the Results of a unripe Phase III Clinical Trial, care with Provenge® (sipuleucel-T), an investigational immunotherapy, improved overall Survival amid men with Metastatic, androgen-independent Prostate Cancer. This Message was Provided in a exert Pressure emancipation from Dendreon on April 14, 2009. More complex Results will be presented later this month at the Annual conference of the American Urological Association.
Provenge is an spry cellular immunotherapeutic envoy that targets the Prostatic acid phosphatase (PAP) Antigen. The PAP Antigen is Stage in approximately 95% of all Prostate cancers. Published Phase I and II Studies of Provenge in Patients with Prostate Cancer show the come near using activated cellular immunotherapy with Provenge is right and provides a future benefit. A U.S. Food and Drug Administration (FDA) Advisory Group has Recommended blessing of Provenge, but this has not yet been done. Two quondam Trials (D9901 and D9902A) included a mount up to of 225 Patients.
continue reading »
Tags:
cancer,
patients,
Prostate,
provenge,
results,
survival
Related posts
February 13th, 2009 -- Posted in Prostate |
The drug, code-named CB7630, is an orally administered inhibitor and is currently in the Phase 3 Trials for the curing of Patients with Chemotherapy naive castration intractable Prostate Cancer. The agreed upon co-primary endpoints of the irritant are Order voluntary Survival and overall Survival, and Cougar expects to initiation the enrolment of Patients later this quarter. Cougar said the European Medicines Agency had also Provided convention in accord with that of the U.S. Food and Drug Administration anent the psychedelic candidate. Shares of the fellowship closed at $30.10 Monday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Gopakumar Warrier).
With respect to site: click there
continue reading »
Tags:
cougar,
patients,
survival
Related posts
